1652 — Fusen Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- HK$188.52m
- HK$573.18m
- CNY326.03m
Annual income statement for Fusen Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 487 | 386 | 492 | 566 | 326 |
| Cost of Revenue | |||||
| Gross Profit | 266 | 211 | 225 | 300 | 163 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 425 | 353 | 486 | 566 | 394 |
| Operating Profit | 61.9 | 32.9 | 5.75 | -0.313 | -67.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 78.4 | 23.8 | -31 | -29.4 | -190 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 62.7 | 16.6 | -34.7 | -36.3 | -189 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 70.1 | 16.6 | -34.6 | -36.3 | -189 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 70.1 | 16.6 | -34.6 | -36.3 | -189 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.112 | 0.05 | -0.012 | -0.03 | -0.255 |
| Dividends per Share |